Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EYA3 | Q99504 | 4/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 12/20 | 0.38 |
| ▸ | TTR | P02766 | 5/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | EYA2 | O00167 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.36 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24103744 | 0.93 | EYA3 (0.42) | EYA3SLC22A12TTRCYP2C19CYP2C9 | |
| SCHEMBL26211957 | 0.90 | EYA3 (0.42) | EYA3SLC22A12TTRCYP2C19CYP2C9 | |
| SCHEMBL20718288 | 0.87 | EYA3 (0.55) | EYA3SLC22A12TTRCYP2C19CYP2C9 | |
| SCHEMBL22072522 | 0.85 | EYA3 (0.45) | EYA3SLC22A12TTRCYP2C19CYP2C9 | |
| SCHEMBL20718309 | 0.85 | EYA3 (0.44) | EYA3SLC22A12TTRCYP2C19CYP2C9 | |
| SCHEMBL20718353 | 0.84 | EYA3 (0.43) | EYA3SLC22A12TTRCYP2C19CYP2C9 | |
| SCHEMBL22680471 | 0.81 | EYA3 (0.54) | EYA3SLC22A12TTRCYP2C19CYP2C9 | |
| SCHEMBL20718531 | 0.79 | EYA3 (0.51) | EYA3SLC22A12TTRCYP2C19CYP2C9 | |
| SCHEMBL24103740 | 0.78 | CYP2C19 (0.32) | EYA3CYP2C19NR1H4 | |
| SCHEMBL24267018 | 0.76 | EYA3 (0.36) | EYA3SLC22A12TTRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227419-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230218563-A1 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | ARTHROSI THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20220024889-A1 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20220023251-A1 | METHODS FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2022-01-27 | — | — | US | disclosed |
| WO-2021252630-A1 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | ARTHROSI THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024889-A1 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | CYP27A1, CYP24A1, CYP27B1 | EYA3 4702/4885SLC22A12 854/4885TTR 117/4885 |
| US-20230227419-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | SLC10A1, UGT1A1, UGT1A3 | EYA3 4188/4885SLC22A12 71/4885TTR 754/4885 |
| US-20220023251-A1 | METHODS FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | CYP27B1, XDH, CYP27A1 | EYA3 4761/4885SLC22A12 830/4885TTR 189/4885 |
| US-20230218563-A1 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | ATP6V1B1, REN, CYP27B1 | EYA3 3141/4885SLC22A12 620/4885TTR 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.